PF-05180999 is primarily investigated for its potential therapeutic applications in the treatment of neurological disorders. It acts as a phosphodiesterase 2 (PDE2) inhibitor, which plays a role in regulating cyclic nucleotides involved in neuronal signaling. By inhibiting PDE2, this compound may enhance cognitive functions such as memory and learning, making it a candidate for addressing conditions like Alzheimer's disease, schizophrenia, and other cognitive impairments. Research is ongoing to evaluate its efficacy and safety in preclinical and clinical studies, with a focus on its ability to modulate brain function and improve symptoms associated with these disorders.